Page last updated: 2024-08-26
sr141716 and Sarcoma
sr141716 has been researched along with Sarcoma in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bifulco, M; D'Alessandro, A; Galgani, M; Gazzerro, P; Laezza, C; Malfitano, AM; Matarese, G | 1 |
Other Studies
1 other study(ies) available for sr141716 and Sarcoma
| Article | Year |
|---|---|
The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ascites; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sarcoma | 2012 |